



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA**  
**Pharmaceuticals & Therapeutics Committee**  
**Department of Health Care Policy & Financing**

Zoom Webinar: TBD  
Tuesday, July 12, 2022, 1:00-5:00 P.M.

**1. Committee Member Introductions**

**2. Unfinished Business and General Orders**

Approval of minutes from April 12, 2022 P&T meeting

Updates from April 12, 2022 P&T Meeting

Tetracyclines

Angiotensin Modifiers - ACE Inhibitors, ARBs

PAH Therapies - PDEIs, Endothelin Antagonists, Prostanoids & Guanylate Cyclase Stimulators

Statins & Combinations

Acne Agents, Topical

Anti-Psoriatics

Immunomodulators, Topical - Atopic Dermatitis, Antineoplastics & Other Agents

Topical Steroids - Low, Medium, High & Very High Potency

Anti-Emetics

H. Pylori Treatments

Pancreatic Enzymes

Anticoagulants

Erythropoiesis Stimulating Agents

Benign Prostatic Hyperplasia (BPH) Agents

Updates on Mass review drug classes:

Alpha-Blockers

Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations

Calcium Channel Blockers - DHPs & Non-DHPs

Angiotensin Modifiers - Renin Inhibitors & Combinations

Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents

Acne Agents, Oral Isotretinoin

Rosacea Agents

Androgenic Agents - Topical, Injectable & Oral

Bile Salts

GI Motility, Chronic

Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents

Proton Pump Inhibitors

Non-Biologic Ulcerative Colitis Agents

Anti-Platelets

Improving health care equity, access, and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



Colony Stimulating Factors  
Phosphate Binders

### 3. New Business

Updates from the Prior Authorization Call Center

### 4. Drug Classes Up for Review

Review of Contraceptives

Oral, Topical

Review of Diabetes Management Classes - Insulins

Rapid-Acting, Long-Acting, Mixtures

Review of Diabetes Management Classes - Non-Insulin

GLP-1 Analogues, SGLT-2is

Review of Glucagon, Self-Administered

Review of Growth Hormones

Mass review drug classes:

- Androgenic Agents - Topical, Injectable, Oral
- Bone Resorption Suppression and Related Agents
- Diabetes Management Classes - Insulins
  - Short, Intermediate
- Diabetes Management Classes - Non-Insulins
  - Amylin, Biguanides, DPP-4is, Meglitinides, TZDs, Combinations
- Estrogen Agents - Oral/Transdermal, Injectable
- Phosphate Binders
- Prenatal Vitamins/Minerals
- Antihyperuricemics
- Benign Prostatic Hyperplasia (BPH) Agents
- Overactive Bladder Agents

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.

Improving health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.  
[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, [jlczechowski@magellanhealth.com](mailto:jlczechowski@magellanhealth.com) and carbon copy: Brittany Schock, PDL Pharmacist, [brittany.schock@state.co.us](mailto:brittany.schock@state.co.us). Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **June 30<sup>th</sup>, 2022 by 5pm MST**.

## 5. Adjourn

Upcoming Meeting Date: October 4, 2022.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

